NCT07685353Recruiting
Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant
Influence of Donor and Recipient PNPLA3 and MBOAT7 Gene Polymorphisms on Graft Liver Steatosis After Living Donor Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Related Cirrhosis
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression. Genetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients. In this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 29 Jun 2026
- Start date
- 7 Jul 2026
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Institute of Liver and Biliary Sciences, India
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07685353
What you commit to
- Study type: Observational
- Planned participants: 50
- From 7 Jul 2026 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Pediatric (\<18 years)
Other
- Transplants for ALF/ ACLF
Who the study is looking for
- All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Liver and Biliary Sciences Coordinator of this site? Confirm its status | New Delhi | India | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.